Catalent Closes Acquisition of Paragon Bioservices
Catalent expands gene therapy capabilities with $1.2-billion acquisition of Paragon Bioservices.
Catalent, Inc. announced on May 20, 2019 the completion of a $1.2-billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing company for gene therapies with expertise in adeno-associated virus vectors. Paragon’s capabilities will enhance Catalent’s biologics business and integrated biopharmaceutical solutions for customers, Catalent reported in a press statement announcing the close of the sale.
Paragon is working on GMP manufacturing projects with more than half of the top 40 leading gene therapy developers worldwide, according to the statement. The company recently opened a commercial manufacturing center near the Baltimore-Washington International airport, which is equipped with several 500-L and 2000-L single-use bioreactors for clinical through commercial material production. The production campus-combined with a leased second building that will be built out for commercial GMP manufacturing-has the potential for more than 425,000-sq.ft. of manufacturing space upon completion, Catalent reports.
Source: Catalent Pharma Solutions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
